PTEN and cutaneous melanoma: Genomic subtyping in cancer is needed for the implementation of molecular therapies and recent TCGA stratification of cutaneous melanomas provides a potential guideline for therapeutic decisions.100 Our results suggest that PTEN expression level could represent a potential biomarker for the implementation of WNT inhibitors in melanoma.